Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials | Zendy

W. Joseph Herring | Zendy; Kathleen M. Connor | Zendy; Ellen Snyder | Zendy; Duane Snavely | Zendy; Ying Zhang | Zendy; Jill Hutzelmann | Zendy; Deborah MatzuraWolfe | Zendy; Ruth M. Benca | Zendy; Andrew D. Krystal | Zendy; James K. Walsh | Zendy; Christopher Lines | Zendy; Thomas Roth | Zendy; David Michelson | Zendy

Open Access

Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials

Author(s) -

W. Joseph Herring,

Kathleen M. Connor,

Ellen Snyder,

Duane Snavely,

Ying Zhang,

Jill Hutzelmann,

Deborah MatzuraWolfe,

Ruth M. Benca,

Andrew D. Krystal,

James K. Walsh,

Christopher Lines,

Thomas Roth,

David Michelson

Publication year - 2016

Publication title -

journal of clinical sleep medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.529

H-Index - 92

eISSN - 1550-9397

pISSN - 1550-9389

DOI - 10.5664/jcsm.6116

Subject(s) - medicine , insomnia , randomized controlled trial , psychiatry , clinical trial , physical therapy , clinical psychology

Suvorexant is an orexin receptor antagonist approved for treating insomnia at a maximum dose of 20 mg. Phase-3 trials evaluated two age-adjusted (non-elderly/elderly) dose-regimes of 40/30 mg and 20/15 mg with the primary focus on 40/30 mg. We report here results from pooled analyses of the 20/15 mg dose-regime, which was evaluated as a secondary objective in the trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research